文献速递肾癌与肾肿瘤

肾细胞癌伴肉瘤样去分化患者接受肾切除术和全身治疗的结局:细胞因子时代与靶向治疗时代的比较

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
PubMed 文献 · J Urol · 2017-04-11

回顾性研究纳入199例肉瘤样肾细胞癌患者,均接受肾切除术和全身治疗,比较细胞因子时代(1987-2005)与靶向治疗时代(2006-2015)的总生存和预后因素。中位总生存16.5个月(95%CI 15.2-20.9),167例(83.9%)死亡。透明细胞组织学生存显著长于非透明细胞组织学(p=0.034),同时性转移生存显著短于异时性转移(中位12.1 vs 23.3个月,p=0.0064)。靶向治疗时代患者第1年生存率显著改善(p=0.011),但该效应在第2年减弱、第3至5年消失,且在不良风险特征患者中不明显。

要点

  • 199例肉瘤样肾细胞癌患者中167例(83.9%)死亡,中位总生存16.5个月(95%CI 15.2-20.9)。
  • 透明细胞组织学生存显著长于非透明细胞组织学(p=0.034)。
  • 同时性转移生存显著短于异时性转移(中位12.1 vs 23.3个月,p=0.0064)。

核心结论

  • 肉瘤样肾细胞癌患者预后仍差,靶向治疗未显示明确的长期获益,作者强调需要开发更有效的全身治疗。

研究设计与样本

  • 回顾性研究,纳入本中心1987至2005年(细胞因子时代)或2006至2015年(靶向治疗时代)接受肾切除术和全身治疗的肉瘤样肾细胞癌患者199例,采用多变量回归模型分析协变量与生存的关联。

主要发现

  • 199例患者中167例(83.9%)死亡,中位总生存16.5个月(95%CI 15.2-20.9)。
  • 透明细胞组织学患者生存显著长于非透明细胞组织学患者(p=0.034)。
  • 同时性转移患者生存显著短于异时性转移患者(中位12.1 vs 23.3个月,p=0.0064)。
  • 原发肿瘤或转移灶活检仅能在7.5%的病例中检测到肉瘤样特征。
  • 靶向治疗时代患者第1年生存率显著改善(p=0.011),但该效应在第2年减弱、第3至5年消失,且在不良风险特征患者中不明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We studied overall survival and prognostic factors in patients with sarcomatoid renal cell carcinoma treated with nephrectomy and systemic therapy in the cytokine and targeted therapy eras. MATERIALS AND METHODS: This is a retrospective study of patients with sarcomatoid renal cell carcinoma who underwent nephrectomy and received systemic therapy at our center in the cytokine era (1987 to 2005) or the targeted therapy era (2006 to 2015). Multivariate regression models were used to determine the association of covariables with survival. RESULTS: Of the 199 patients with sarcomatoid renal cell carcinoma 167 (83.9%) died (median overall survival 16.5 months, 95% CI 15.2-20.9). Survival of patients with clear cell histology was significantly longer vs those with nonclear cell histology (p = 0.034). Patients with synchronous metastatic disease had significantly shorter survival than patients with metachronous metastatic disease (median 12.1 vs 23.3 months, p = 0.0064). Biopsy of the primary tumor or a metastatic site could detect the presence of sarcomatoid features in only 7.5% of cases. Although a significant improvement in survival rate was observed in the first year in patients treated in the targeted therapy era (p = 0.011), this effect was attenuated at year 2, disappeared at years 3 to 5 after diagnosis and was not evident in patients with poor risk features. CONCLUSIONS: Patients with sarcomatoid renal cell carcinoma still have poor prognosis with no clear long-term benefit of targeted therapy. This underscores the need to develop more effective systemic therapies for these patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Keskin SK, Msaouel P, Hess KR, et al. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017. PMID: 28411072. doi:10.1016/j.juro.2017.04.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。